Etanercept biosimilars

@inproceedings{Azevedo2014EtanerceptB,
  title={Etanercept biosimilars},
  author={Valderilio Feij{\'o} Azevedo and Nathalia Galli and Alais Daiane Fadini Kleinfelder and Julia D’Ippolito and Paulo C. M. Urbano},
  booktitle={Rheumatology International},
  year={2014}
}
Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being cheaper alternatives to the reference product. In a global scenario that is favourable to the entry of biosimilars, this article discusses the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.
15 Citations
93 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 93 references

Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein

  • H Zhou
  • J Clin Pharmacol 45:490–497
  • 2005
Highly Influential
6 Excerpts

Analytical characterization of biosimilar antibodies and Fc-fusion proteins

  • A Beck, H Diemer, D Ayoub
  • TrAC, Trends Anal Chem
  • 2013
3 Excerpts

Coherus announces CHS-0214 (proposed etanercept biosimilar) meets primary endpoint in pivotal pharmacokinetic clinical study

  • C Biosciences
  • http://www.coherus.com/pressreleases/coherus…
  • 2013

Similar Papers

Loading similar papers…